Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery?

I. Miron, D. Frappaz, M. Brunat-Mentigny, V. Combaret, M. Buclon, E. Bouffet, P. Thiesse, Susanne Ragg, C. Bailly, T. Philip

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This retrospective study compared the overall survival, the event-free survival, and the timing of chemotherapy in patients with advanced Burkitt lymphoma with and without laparotomy. Thirty-five patients with advanced abdominal Burkitt lymphoma treated at least partially at the Centre Leon Berard between 1981 and 1992 were included in this study. The diagnosis was obtained by laparotomy (LAP group) in 21 patients (17 stage III, 4 stage IV) and by other methods (non-LAP group) in 14 patients (5 stage III, 9 stage IV). The overall survival (71 and 93 %) and the event-free survival (66 and 79%) were similar in the LAP and non-LAP groups, and the relapse rate was five (three local) in the LAP group compared with three (none local) in the non-LAP group. The local complication rate (9 of 21 versus 2 of 14) and the toxic death rate (2 of 21 versus 1 of 14) were slightly higher in the LAP group. Laparotomy also caused delays in therapy and increased the overall hospital stay. The mean interval from diagnosis to the start of the fourth course of chemotherapy was 57 days compared with 48 days and the average hospital stay was 44.4 days compared with 39 days for the LAP and non-LAP groups, respectively. Because advanced Burkitt lymphoma can be diagnosed by fine-needle aspiration, and chemotherapy cures more than 80% of the patients, there is no need for initial surgery, apart from acute emergencies. Furthermore, laparotomy delays chemotherapy and might reduce the survival rate.

Original languageEnglish (US)
Pages (from-to)555-561
Number of pages7
JournalPediatric Hematology and Oncology
Volume14
Issue number6
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Chemotherapy
Burkitt Lymphoma
Surgery
Laparotomy
Drug Therapy
Disease-Free Survival
Length of Stay
Needles
Survival
Poisons
Fine Needle Biopsy
Emergencies
Survival Rate
Retrospective Studies
Lymphoma
Recurrence
Mortality

Keywords

  • Burkitt lymphoma
  • Chemotherapy
  • Children
  • Lymphoma
  • Surgery

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Cite this

Miron, I., Frappaz, D., Brunat-Mentigny, M., Combaret, V., Buclon, M., Bouffet, E., ... Philip, T. (1997). Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery? Pediatric Hematology and Oncology, 14(6), 555-561.

Initial management of advanced Burkitt lymphoma in children : Is there still a place for surgery? / Miron, I.; Frappaz, D.; Brunat-Mentigny, M.; Combaret, V.; Buclon, M.; Bouffet, E.; Thiesse, P.; Ragg, Susanne; Bailly, C.; Philip, T.

In: Pediatric Hematology and Oncology, Vol. 14, No. 6, 11.1997, p. 555-561.

Research output: Contribution to journalArticle

Miron, I, Frappaz, D, Brunat-Mentigny, M, Combaret, V, Buclon, M, Bouffet, E, Thiesse, P, Ragg, S, Bailly, C & Philip, T 1997, 'Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery?', Pediatric Hematology and Oncology, vol. 14, no. 6, pp. 555-561.
Miron I, Frappaz D, Brunat-Mentigny M, Combaret V, Buclon M, Bouffet E et al. Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery? Pediatric Hematology and Oncology. 1997 Nov;14(6):555-561.
Miron, I. ; Frappaz, D. ; Brunat-Mentigny, M. ; Combaret, V. ; Buclon, M. ; Bouffet, E. ; Thiesse, P. ; Ragg, Susanne ; Bailly, C. ; Philip, T. / Initial management of advanced Burkitt lymphoma in children : Is there still a place for surgery?. In: Pediatric Hematology and Oncology. 1997 ; Vol. 14, No. 6. pp. 555-561.
@article{3acf9707c4a249b48abc8fdcb634b141,
title = "Initial management of advanced Burkitt lymphoma in children: Is there still a place for surgery?",
abstract = "This retrospective study compared the overall survival, the event-free survival, and the timing of chemotherapy in patients with advanced Burkitt lymphoma with and without laparotomy. Thirty-five patients with advanced abdominal Burkitt lymphoma treated at least partially at the Centre Leon Berard between 1981 and 1992 were included in this study. The diagnosis was obtained by laparotomy (LAP group) in 21 patients (17 stage III, 4 stage IV) and by other methods (non-LAP group) in 14 patients (5 stage III, 9 stage IV). The overall survival (71 and 93 {\%}) and the event-free survival (66 and 79{\%}) were similar in the LAP and non-LAP groups, and the relapse rate was five (three local) in the LAP group compared with three (none local) in the non-LAP group. The local complication rate (9 of 21 versus 2 of 14) and the toxic death rate (2 of 21 versus 1 of 14) were slightly higher in the LAP group. Laparotomy also caused delays in therapy and increased the overall hospital stay. The mean interval from diagnosis to the start of the fourth course of chemotherapy was 57 days compared with 48 days and the average hospital stay was 44.4 days compared with 39 days for the LAP and non-LAP groups, respectively. Because advanced Burkitt lymphoma can be diagnosed by fine-needle aspiration, and chemotherapy cures more than 80{\%} of the patients, there is no need for initial surgery, apart from acute emergencies. Furthermore, laparotomy delays chemotherapy and might reduce the survival rate.",
keywords = "Burkitt lymphoma, Chemotherapy, Children, Lymphoma, Surgery",
author = "I. Miron and D. Frappaz and M. Brunat-Mentigny and V. Combaret and M. Buclon and E. Bouffet and P. Thiesse and Susanne Ragg and C. Bailly and T. Philip",
year = "1997",
month = "11",
language = "English (US)",
volume = "14",
pages = "555--561",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Initial management of advanced Burkitt lymphoma in children

T2 - Is there still a place for surgery?

AU - Miron, I.

AU - Frappaz, D.

AU - Brunat-Mentigny, M.

AU - Combaret, V.

AU - Buclon, M.

AU - Bouffet, E.

AU - Thiesse, P.

AU - Ragg, Susanne

AU - Bailly, C.

AU - Philip, T.

PY - 1997/11

Y1 - 1997/11

N2 - This retrospective study compared the overall survival, the event-free survival, and the timing of chemotherapy in patients with advanced Burkitt lymphoma with and without laparotomy. Thirty-five patients with advanced abdominal Burkitt lymphoma treated at least partially at the Centre Leon Berard between 1981 and 1992 were included in this study. The diagnosis was obtained by laparotomy (LAP group) in 21 patients (17 stage III, 4 stage IV) and by other methods (non-LAP group) in 14 patients (5 stage III, 9 stage IV). The overall survival (71 and 93 %) and the event-free survival (66 and 79%) were similar in the LAP and non-LAP groups, and the relapse rate was five (three local) in the LAP group compared with three (none local) in the non-LAP group. The local complication rate (9 of 21 versus 2 of 14) and the toxic death rate (2 of 21 versus 1 of 14) were slightly higher in the LAP group. Laparotomy also caused delays in therapy and increased the overall hospital stay. The mean interval from diagnosis to the start of the fourth course of chemotherapy was 57 days compared with 48 days and the average hospital stay was 44.4 days compared with 39 days for the LAP and non-LAP groups, respectively. Because advanced Burkitt lymphoma can be diagnosed by fine-needle aspiration, and chemotherapy cures more than 80% of the patients, there is no need for initial surgery, apart from acute emergencies. Furthermore, laparotomy delays chemotherapy and might reduce the survival rate.

AB - This retrospective study compared the overall survival, the event-free survival, and the timing of chemotherapy in patients with advanced Burkitt lymphoma with and without laparotomy. Thirty-five patients with advanced abdominal Burkitt lymphoma treated at least partially at the Centre Leon Berard between 1981 and 1992 were included in this study. The diagnosis was obtained by laparotomy (LAP group) in 21 patients (17 stage III, 4 stage IV) and by other methods (non-LAP group) in 14 patients (5 stage III, 9 stage IV). The overall survival (71 and 93 %) and the event-free survival (66 and 79%) were similar in the LAP and non-LAP groups, and the relapse rate was five (three local) in the LAP group compared with three (none local) in the non-LAP group. The local complication rate (9 of 21 versus 2 of 14) and the toxic death rate (2 of 21 versus 1 of 14) were slightly higher in the LAP group. Laparotomy also caused delays in therapy and increased the overall hospital stay. The mean interval from diagnosis to the start of the fourth course of chemotherapy was 57 days compared with 48 days and the average hospital stay was 44.4 days compared with 39 days for the LAP and non-LAP groups, respectively. Because advanced Burkitt lymphoma can be diagnosed by fine-needle aspiration, and chemotherapy cures more than 80% of the patients, there is no need for initial surgery, apart from acute emergencies. Furthermore, laparotomy delays chemotherapy and might reduce the survival rate.

KW - Burkitt lymphoma

KW - Chemotherapy

KW - Children

KW - Lymphoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=9844256101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844256101&partnerID=8YFLogxK

M3 - Article

C2 - 9383808

AN - SCOPUS:9844256101

VL - 14

SP - 555

EP - 561

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 6

ER -